Abstract
Naphthalimides, a class of compounds which bind to DNA by intercalation, have shown high anti-cancer activity against a variety of murine and more notably human cancer cell lines. Azonafide derivatives are also potential antitumor agents which are structurally related to the naphthalimides. Derivatives of azonafide have shown enhanced activity against various cancer models, especially leukemias, breast cancer and melanoma. Naphthalimides in general and amonafide in particular, are most probably the agents which have been involved in the greatest number of clinical trials without ever acceding to the market because of dose-limiting toxicity. This statement also reflects the immense interest that oncologists have paid to this class of compounds with respect to their anti-cancer potential. While the first generation of naphthalimides were mainly topoisomerse II poisons, some new compounds display novel mechanism of action. In contrast to the most widely used topo II poisons, including etoposide, adriamycin and their analogues, which often induce multi-drug resistance, several naphthalimide-related compounds have been reported not to be affected by this phenomenon. Multi-disciplinary approaches including medicinal chemistry, early toxicology and DMPK, in vivo activity assessment in diverse preclinical models and in-depth mechanism of action deciphering, along with the lessons learnt from previous and currently ongoing clinical trials, have resulted in the generation of a number of novel promising naphthalimide derivatives. It is thus reasonable to expect that members of this class of compounds will reach the oncology market in the near future.
Keywords: Anti-Cancer Agents, Azonafides, Naphthalimides, leukemias, breast cancer, medicinal chemistry, DMPK
Current Medicinal Chemistry
Title: Naphthalimides and Azonafides as Promising Anti-Cancer Agents
Volume: 16 Issue: 10
Author(s): Laurent Ingrassia, Florence Lefranc, Robert Kiss and Tatjana Mijatovic
Affiliation:
Keywords: Anti-Cancer Agents, Azonafides, Naphthalimides, leukemias, breast cancer, medicinal chemistry, DMPK
Abstract: Naphthalimides, a class of compounds which bind to DNA by intercalation, have shown high anti-cancer activity against a variety of murine and more notably human cancer cell lines. Azonafide derivatives are also potential antitumor agents which are structurally related to the naphthalimides. Derivatives of azonafide have shown enhanced activity against various cancer models, especially leukemias, breast cancer and melanoma. Naphthalimides in general and amonafide in particular, are most probably the agents which have been involved in the greatest number of clinical trials without ever acceding to the market because of dose-limiting toxicity. This statement also reflects the immense interest that oncologists have paid to this class of compounds with respect to their anti-cancer potential. While the first generation of naphthalimides were mainly topoisomerse II poisons, some new compounds display novel mechanism of action. In contrast to the most widely used topo II poisons, including etoposide, adriamycin and their analogues, which often induce multi-drug resistance, several naphthalimide-related compounds have been reported not to be affected by this phenomenon. Multi-disciplinary approaches including medicinal chemistry, early toxicology and DMPK, in vivo activity assessment in diverse preclinical models and in-depth mechanism of action deciphering, along with the lessons learnt from previous and currently ongoing clinical trials, have resulted in the generation of a number of novel promising naphthalimide derivatives. It is thus reasonable to expect that members of this class of compounds will reach the oncology market in the near future.
Export Options
About this article
Cite this article as:
Ingrassia Laurent, Lefranc Florence, Kiss Robert and Mijatovic Tatjana, Naphthalimides and Azonafides as Promising Anti-Cancer Agents, Current Medicinal Chemistry 2009; 16 (10) . https://dx.doi.org/10.2174/092986709787846659
DOI https://dx.doi.org/10.2174/092986709787846659 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Liver and Pancreatic Disease in Cystic Fibrosis: Clinics and Drug Therapy
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Medicinal Compound Celastrol As a Potential Clinical Anticancer Drug: Lessons Learned From Preclinical Studies
Clinical Cancer Drugs The Effect of Quercetin on Doxorubicin Cytotoxicity in Human Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Tubulin-Independent Tau in Alzheimer’s Disease and Cancer: Implications for Disease Pathogenesis and Treatment
Current Alzheimer Research Microemulsions and Nanoemulsions for Targeted Drug Delivery to the Brain
Current Nanoscience HLA Class I Expression, Tumor Escape and Cancer Progression
Current Cancer Therapy Reviews Low Dose Aspirin, COX-Inhibition and Chemoprevention of Colorectal Cancer
Current Topics in Medicinal Chemistry A Fast and Efficient Chemiluminescence Method for Determination and Pharmacokinetic Study of Paclitaxel in Rat Plasma
Current Pharmaceutical Analysis Aging and Inflammation: Etiological Culprits of Cancer
Current Aging Science The Role of Reactive Species in Epileptogenesis and Influence of Antiepileptic Drug Therapy on Oxidative Stress
Current Neuropharmacology Editorial (Thematic Issue: Revisiting the Revolution: Examining the Evolving Role of Antiangiogenic Therapy in Cancer)
Current Drug Targets Microdialysis: A Technique for Pharmacokinetic-Pharmacodynamic Studies of Oncological Drugs
Current Pharmaceutical Biotechnology PET Imaging of Multidrug Resistance in Tumors Using 18F-Fluoropaclitaxel
Current Topics in Medicinal Chemistry Ionic Liquid Mediated Synthesis of Novel tetrahydroimidazo [1,2- a]pyrimidine-6-carboxylate Derivatives
Letters in Organic Chemistry Post-translational and Post-transcriptional Modifications of Pregnane X Receptor (PXR) in Regulation of the Cytochrome P450 Superfamily
Current Drug Metabolism Large-Scale Production Means for the Manufacturing of Lentiviral Vectors
Current Gene Therapy Cyclophilin A as a Target of Cisplatin Chemosensitizers
Current Cancer Drug Targets A Review on Noscapine, and its Impact on Heme Metabolism
Current Drug Metabolism Ultrasmall Nanoclusters: Synthesis and Applications as an Emerging Platform for Imaging and Therapy
Current Analytical Chemistry Nanocarriers for the Simultaneous Co-Delivery of Therapeutic Genes and Anticancer Drugs
Current Pharmaceutical Biotechnology